New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - prazosin hydrochloride 1.1mg equivalent to 1 mg prazosin - tablet - 1 mg - active: prazosin hydrochloride 1.1mg equivalent to 1 mg prazosin excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - prazosin hydrochloride 2.2mg equivalent to 2 mg prazosin - tablet - 2 mg - active: prazosin hydrochloride 2.2mg equivalent to 2 mg prazosin excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains prazosin hydrochloride equivalent to prazosin 1 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains prazosin hydrochloride equivalent to prazosin 2 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - prazosin hydrochloride -

Namibia - English - Namibia Medicines Regulatory Council

pharmacare limited - prazosin hcl 1 mg - tablet - prazosin hcl 1 mg

Namibia - English - Namibia Medicines Regulatory Council

pharmacare limited - prazosin hcl 2 mg - tablet - prazosin hcl 2 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.0625mg;  ;  ;  ;  ; digoxin 0.0625mg - tablet - 0.0625 mg - active: digoxin 0.0625mg         excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified water rice starch active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - prazosin hydrochloride - tablets - 5 milligram